Search clinical trials for: erlotinib

Total 1379 results

National Cancer Institute (NCI)

Terminated

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Intraductal Papillary Mucinous Neoplasm of the Pancreas

United States
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
Novartis Pharmaceuticals

Completed

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE)

Chronic Myeloid Leukemia

Germany
Henan Cancer Hospital

Completed

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Extensive Disease Small Cell Lung Cancer

China
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
Yizhuo Zhang

Unknown

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Differentiated Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing... and other collaborators

Unknown

Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy

Soft Tissue Sarcoma

China
Hospital for Special Surgery, New York
Novartis Pharmaceuticals; Rudolph Rupert Scleroderma Program

Completed

Nilotinib in the Treatment of Systemic Sclerosis

Systemic Sclerosis

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University

Completed

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (ALTN)

Advanced Cancer

China
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Dutch Society of Physicians for Pulmonology and...

Completed

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) (NVALT10)

Carcinoma, Non-Small-Cell Lung

Netherlands
Northwestern University
Robert H. Lurie Cancer Center

Completed

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Adenocarcinoma of the Lung

United States
Lyudmila Bazhenova, M.D.
AstraZeneca

Terminated

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Duke University
Genentech, Inc.; OSI Pharmaceuticals

Completed

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Glioblastoma | Gliosarcoma

United States
The Netherlands Cancer Institute
Dutch Society of Physicians for Pulmonology and Tuberculosis

Terminated

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Carcinoma, Non-small Cell Lung

Netherlands
M.D. Anderson Cancer Center

Completed

Study of Erlotinib in Combination With Bortezomib

Advanced Cancer

United States
Fatebenefratelli and Ophthalmic Hospital
Niguarda Hospital; Mario Negri Institute for Pharmacological Research

Unknown

Tarceva Italian Lung Optimization tRial (TAILOR)

Non Small Cell Lung Cancer (NSCLC)

Italy
Accelerated Community Oncology Research Network
GlaxoSmithKline; Genentech, Inc.

Completed

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Metastatic Solid Tumor

United States
Sanofi

Terminated

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Liver Carcinoma

France
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Shanghai Gopherwood Biotech Co., Ltd.

Not yet recruiting

BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer (CAN-RESPOND)

Endometrial Cancer
Henan Cancer Hospital

Recruiting

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Desmoid

China
Shanghai Chest Hospital
3D Medicines

Not yet recruiting

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Anlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications

China
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
Taizhou Hospital

Completed

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Small Cell Lung Cancer Recurrent

China
Novartis Pharmaceuticals

Completed

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chronic Myeloid Leukemia

Germany
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
The First Hospital of Jilin University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

Non-Small Cell Lung Cancer

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital; Yan'an University Affiliated Hospital

Unknown

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Esophageal Squamous Cell Carcinoma

China
LanZhou University
General Hospital of Ningxia Medical University

Unknown

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Advanced Non-squamous NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Gastric Cancer

China
Seoul National University Hospital
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Nilotinib in CML-CP (ENESTKorea)

Chronic Myeloid Leukemia, Chronic Phase
Indiana University
Novartis

Completed

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis | NF1 | Neurofibromas

United States
University of California, San Francisco

Completed

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma (AVF4120s)

Glioblastoma | Gliosarcoma

United States
Dartmouth-Hitchcock Medical Center
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

United States
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Completed

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Brain Cancer | Non-small Cell Lung Cancer

United States
Washington University School of Medicine

Terminated

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer

United States
St. Jude Children's Research Hospital
Duke University; Rady Children's Hospital, San Diego

Completed

Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma

Brain and Central Nervous System Tumors

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Spain, United Kingdom, Belgium
University Hospital, Limoges
Hoffmann-La Roche

Completed

Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer (TARSEQ)

Non Small Cell Lung Cancer

France

Search clinical trials for: erlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations